{
    "eid": "2-s2.0-85148307020",
    "title": "Antidrug Antibodies to Tumor Necrosis Factor \u03b1 Inhibitors in Patients with Noninfectious Uveitis",
    "cover-date": "2023-02-16",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Ophthalmology",
            "@code": "2731",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Sunil Bellur",
        "Matthew McHarg",
        "Wijak Kongwattananon",
        "Susan Vitale",
        "H. Nida Sen",
        "Shilpa Kodati"
    ],
    "citedby-count": 1,
    "ref-count": 26,
    "ref-list": [
        "Adalimumab in patients with active noninfectious uveitis",
        "Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial",
        "Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: A multicenter study from the French Uveitis Network",
        "Biologics for the treatment of noninfectious uveitis: Current concepts and emerging therapeutics",
        "Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis",
        "Adalimumab for treatment of noninfectious uveitis: Immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies",
        "Anti-adalimumab antibodies in patients with non-infectious ocular inflammatory disease: A case series",
        "Immunogenicity of TNF-inhibitors",
        "Comparative immunogenicity of TNF inhibitors: Impact on clinical efficacy and tolerability in the management of autoimmune diseases. a systematic review and meta-analysis",
        "Anti-adalimumab antibodies kinetics: An early guide for juvenile idiopathic arthritis (JIA) switching",
        "Immunogenicity and autoimmunity during anti-TNF therapy",
        "HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease",
        "Immunogenicity of anti-TNF\u03b1 therapy in psoriasis: A clinical issue?",
        "Primary and secondary nonresponse to infliximab: Mechanisms and countermeasures",
        "Anti-TNF monoclonal antibodies in inflammatory bowel disease: Pharmacokinetics-based dosing paradigms",
        "Clinical response to adalimumab: Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis",
        "The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis",
        "The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease",
        "Immunogenicity of anti-TNF-\u03b1 agents in autoimmune diseases",
        "Immunosuppression for the uveitides",
        "Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: A retrospective study",
        "Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease",
        "Evaluation of therapeutic drug monitoring in the clinical management of patients with rheumatic diseases: Data from a retrospective single-center cohort study",
        "Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: A systematic review",
        "Update on therapeutic drug monitoring in crohn's disease",
        "American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease"
    ],
    "affiliation": [
        {
            "affiliation-city": "Washington, D.C.",
            "@id": "60025286",
            "affilname": "The George Washington University School of Medicine and Health Sciences",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025286",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bethesda",
            "@id": "60007651",
            "affilname": "National Eye Institute (NEI)",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007651",
            "affiliation-country": "United States"
        }
    ],
    "funding": []
}